Short to mid-term outcomes of flow re-direction endoluminal device X (FREDTM X) in the management of intracranial aneurysms: a meta-analysis

This meta-analysis evaluates the clinical and angiographic outcomes of the flow re-direction endoluminal device X (FRED<sup>TM</sup> X) in treating intracranial aneurysms. A systematic review was performed across Medline, Scopus, and Web of Science databases from inception to March 2025. Eligible studies included those reporting clinical and angiographic results of FRED X treatment. Favorable outcomes were defined as those stated explicitly in the studies or a modified Rankin scale score of 0-2. Pooled estimates were calculated using a random-effects model in R. A total of nine studies encompassing 780 patients with 869 aneurysms were included. The weighted mean age was 56.28 years, with 19.1% of patients being men. Most aneurysms were saccular (85.7%), unruptured (92.52%), and located in the anterior circulation (73.6%), primarily in the internal carotid artery. The average aneurysm size was 13.12 mm. All studies employed dual antiplatelet therapy, with antiplatelet response testing performed in eight studies. The mean clinical follow-up period was 9.27 months. The meta-analysis demonstrated favorable neurological outcomes in 97.71% of cases and complete or near-complete occlusion in 86.9%. Procedure-related complications were reported in 9.28% of cases, while in-stent thrombosis or intimal hyperplasia occurred in 4.29%. Overall mortality was low at 0.60%. Subgroup analysis revealed that unruptured aneurysms had a 100% rate of favorable neurological outcomes and an 84.76% rate of complete or near-complete occlusion. Complication and mortality rates were 7.76% and 0.25%, respectively. In addition, favorable outcomes were seen in 100% of ruptured aneurysm cases; however, complete occlusion was achieved in only 59.65%, and the mortality rate was higher at 9.19%. Therefore, FRED X demonstrated high efficacy and procedural safety in the treatment of intracranial aneurysms, offering improved outcomes compared with earlier-generation flow diverters.

Authors

Institutions

Publication Details

Journal
Diagnostic and Interventional Radiology
Published
2025-07-21
DOI
https://doi.org/10.4274/dir.2025.253309
Citations
1
Primary Topic
Intracranial Aneurysms: Treatment and Complications
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Short to mid-term outcomes of flow re-direction endoluminal device X (FREDTM X) in the management of intracranial aneurysms: a meta-analysis

İsmail Oran, Celal Çınar, Mahmut Küsbeci, Alperen Elek et al.
1 citations
Diagnostic and Interventional Radiology
Intracranial Aneurysms: Treatment and Complications
1.39
article

Short to mid-term outcomes of flow re-direction endoluminal device X (FREDTM X) in the management of intracranial aneurysms: a meta-analysis

İsmail Oran, Celal Çınar, Mahmut Küsbeci, Alperen Elek, Gülfem Nur Dindar, Sidar Karagöz, Eda Teomete, Semra Yücel, Egemen Öztürk
article en
1 citations

Abstract

This meta-analysis evaluates the clinical and angiographic outcomes of the flow re-direction endoluminal device X (FRED<sup>TM</sup> X) in treating intracranial aneurysms. A systematic review was performed across Medline, Scopus, and Web of Science databases from inception to March 2025. Eligible studies included those reporting clinical and angiographic results of FRED X treatment. Favorable outcomes were defined as those stated explicitly in the studies or a modified Rankin scale score of 0-2. Pooled estimates were calculated using a random-effects model in R. A total of nine studies encompassing 780 patients with 869 aneurysms were included. The weighted mean age was 56.28 years, with 19.1% of patients being men. Most aneurysms were saccular (85.7%), unruptured (92.52%), and located in the anterior circulation (73.6%), primarily in the internal carotid artery. The average aneurysm size was 13.12 mm. All studies employed dual antiplatelet therapy, with antiplatelet response testing performed in eight studies. The mean clinical follow-up period was 9.27 months. The meta-analysis demonstrated favorable neurological outcomes in 97.71% of cases and complete or near-complete occlusion in 86.9%. Procedure-related complications were reported in 9.28% of cases, while in-stent thrombosis or intimal hyperplasia occurred in 4.29%. Overall mortality was low at 0.60%. Subgroup analysis revealed that unruptured aneurysms had a 100% rate of favorable neurological outcomes and an 84.76% rate of complete or near-complete occlusion. Complication and mortality rates were 7.76% and 0.25%, respectively. In addition, favorable outcomes were seen in 100% of ruptured aneurysm cases; however, complete occlusion was achieved in only 59.65%, and the mortality rate was higher at 9.19%. Therefore, FRED X demonstrated high efficacy and procedural safety in the treatment of intracranial aneurysms, offering improved outcomes compared with earlier-generation flow diverters.

Diagnostic and Interventional RadiologyVol. 32(2)
Dicle University (TR), University of Michigan (US), Ege University (TR), Michigan Medicine (US), Gazi University (TR), Kastamonu University (TR)
Openalex Percentile: Top 17%
Intracranial Aneurysms: Treatment and Complications
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.